To access abstracts of some of the published articles on Pub Med click on this link and copy the article name in the search box Articles In Press, Awaiting Publication

     Berge JM, Patterson JM, Goetz D, Milla CE. Young Adults' Perceptions of living with Cystic Fibrosis during the transition to adulthood: A qualitative investigation. (In press, Families, Sytems and Health).

     Sabati AA, Kempainen RR, Milla CE, Ireland M, Blumenthal MN, Schwarzenberg SJ, Dunitz JM, Kahn KM. Gastroesophageal reflux in 201 adults with cystic fibrosis. (In Review for Publication Chest).

Articles Recently Submitted for Publication

Paterson JM, Berge J, Wall M, Milla CE. Associations of Gender Differences in Feelings and Behaviors with Health Outcomes among youth with Cystic Fibrosis. (In review for publication Journal of Adolescent Health).

     Patterson J, Wall M, Berge J, Milla C. Examining gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire. (In review for publication J Pediatr Psychol).

     Gibson RL, Emerson J, Hamblett N, Burns JL, McNamara S, Accurso F, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz D, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW for the Inhaled Tobramycin in Young Children Study Group and the Cystic Fibrosis Foundation Therapeutics Development Network. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Submitted, Am Rev Respir Crit Care Med.

     Zirbes JM, Milla CE. Steroid-sparing effect of Omalizumab in the managment of severe Allergic Bronchopulmonary Aspergillosis in a child with cystic fibrosis. (Submitted, Pediatric Pulmonology )

     Billings JL, Milla CE. Clinical characteristics associated with the presence of a CF pulmonary exacerbation. (Submitted, Chest).

     Robinson TE, Chen X, Moss RB. Chest HRCT discriminates bacterial infection effects on disease severity in children with mild cystic fibrosis. Submitted, Am Rev Respir Crit Care Med.

     Moss RB, Milla C, Colombo J, Accurso F, Zeitlin P, Clancy JP, Spencer T, Pilewski J,Waltz DA, Dorkin H, Ferkol T, Pian M, Ramsey B, Anklesaria P, Martin D, Heald AE. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo controlled Phase IIB trial. Submitted Human Gene Therapy.

     Tirouvanziam R, Moss RB, Conrad CK, Dunn CE, Davies Z, Herzenberg LA, Herzenberg LA. Distinct cellular dysfunction of live airway neutrophils underlies cystic fibrosis lung disease. Submitted, J Allergy Clin Immunol

     Billings JL, Carlquist D, Milla CE. Efects of myostatin (GDF8) on muscle mass and rate of pulmonary function decline in patients with Cystic Fibrosis. (Submitted, J Cystic Fibrosis).

     Borowitz D, Hamblett N, Konstan MW, Milla C, Hendeles L, Murray S, Cornelisse P , Kronmal R, Casey S, Rose L, Folger Bruce K, Morgan W, Ramsey B. Optimal study design for evaluating the efficacy and safety of orally administered pancreatic enzyme replacement therapy (PERT). (In preparation for submission to Pharmacotherapy).

     Milla C, Moran A, Dunitz J, Billings J, Schwarzenberg SJ. Body Mass Index and Clinical Outcomes in Cystic Fibrosis. (Submitted, Chest).

     Moss RB. Inhalational antibiotics for airways infections. Exper Lung Res, in press.

2007 Publications

     Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla CE, Moran A. Microvascular Complications in Cystic Fibrosis Related Diabetes. Diabetes Care. 2007 May;30(5):1056-61. Epub 2007 Feb 23.

     Perdue DG, Schwarzenberg SJ, Cass OW, Milla CE, Dunitz J, Jessurun J, Sharp HL. Hepatolithiasis and Cholangiocarcinoma in Cystic Fibrosis. Dig Dis Sci. 2007 Apr 19; [Epub ahead of print] No abstract available.

     Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson RL, Zeitlin P, Berclaz Y, Moss R, Knowles M, Oster RA, Mayer-Hamblett N, Ramsey B. No detectable improvements in CFTR by nasal aminoglycosides in CF patients heterozygous for stop mutations. Am J Respir Cell Molec Biol 2007 Mar 8; [Epub ahead of print]

     Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):212-8

     Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety.Pediatr Pulmonol. 2007 Apr;42(4):307-13

     Faro A, Mallory GB, Visner GA, Elidemir O, Mogayzel PJ Jr, Danziger-Isakov L, Michaels M, Sweet S, Michelson P, Paranjape S, Conrad C, Waltz DA; American Society of Transplantation. American Society of Transplantation executive summary on pediatric lung transplantation. Am J Transplant. 2007 Feb;7(2):285-92. Epub 2006 Nov 15.

2006 Publications

     Venkatraman R, Raman R, Raman B, Moss RB, Rubin GD, Mathers LH, Robinson TE. Fully automated system for three-dimensional bronchial morphology analysis using volumetric multidetector computed tomography of the chest. J Digit Imaging, 13 Dec 2006 ePub ahead of print; 2006 Jun;19(2):132-9

     Ferkol T, Rosenfeld M, Milla CE. Cystic Fibrosis pulmonary exacerbations. Journal of Pediatrics 2006; 148:259-264.

     Gibson RL, Retsch-Bogart GZ, Oermann C, Milla CE, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, Safety, and Pharmacokinetics of Aztreonam Lysinate for Inhalation in Patients with Cystic Fibrosis 1: Pediatr Pulmonol. 2006 Jul;41(7):656-65

     Kurup VP, Knutsen AP, Moss RB, Bansal N. Demonstration of specific antibodies to recombinant Aspergillus allergens in cystic fibrosis patients with ABPA. Clin Molec Allergy 4:11-18, 2006.

     Milla CE. Cystic Fibrosis Related Diabetes (Review). Current Medical Literature - Diabetes 2006; 23:33-38.

     Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 103:4628-4633, 2006.

     Moss RB. Clinical trials in allergic bronchopulmonary aspergilllosis and fungal allergy. Med Mycol 44:S269-S272, 2006.

     Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR Jr, Dunitz J, Murray FT. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006 Apr;32(3):258-63.

     Milla CE, Hansen LG, Warwick WJ. Different frequencies should be prescribed for different High Frequency Chest Compression (HFCC) machines. Biomed Instrumentation Technol 2006; 40:319-324.

2005 Publications

     Sheridan MB, Fong P, Groman JD, Conrad C, Flume P, Diaz R, Harris C, Knowles M, Cutting GR. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005 Nov 15;14(22):3493-8. Epub 2005 Oct 5.

     Brody AS, Tiddens HA, Castile RG, Coxson HO, de Jong PA, Goldin J, Huda W, Long FR, McNitt-Gray M, Rock M, Robinson TE, Sagel SD; CT Scanning in Cystic Fibrosis Special Interest Group.Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med.2005 Nov 15;172(10):1246-52. Epub 2005 Aug 11.

     Xiao W, Hsu YP, Ishizaka A, Kirikae, Moss RB. Sputum cathelicidin, plasmin activation system components and cytokine patterns discriminate cystic fibrosis, chronic obstructive pulmonary disease and asthma from each other and healthy subjects. Chest 128:2316-2326, 2005.

     Schrijver I, Karnsakul W, Ramalingam S, Sankaran R, Moss R, Gardner P. Novel contributions to the Asian CFTR mutation spectrum: genotype and phenotype in Thai patients with cystic fibrosis. Am J Med Genet 133A:103-105, 2005.

     Schrijver I, Ramalingam S, Sankaran R, Swanson S, Dunlop CLM, Keiles S, Wassman EF, Moss RB, Oehlert J, Gardner P, Kammesheidt. Diagnostic testing by comprehensive mutation analysis in a large group of Hispanics: novel mutations and assessment of a population-specific mutation spectrum. J Molec Diagnostics 7:289-299, 2005.

     Bonnel AS, Song, SMH, Kesavarju K, Newaskar M, Paxton CJ, Bloch DA, Moss RB, Robinson TE. Quantitative air trapping analysis in children with mild cystic fibrosis lung disease. Pediatr Pulmonol 2004; 38:396-405.

     Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sathi A, Sheikh F, Moss RB. Dornase alpha reduces air trapping in children with mild CF lung disease: a quantitative analysis. Chest 128:2327-2335, 2005.

     Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz DA, Zeitlin P, Ramsey B, , Starko K. A randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39:209-218, 2005.

     Deterding RR, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin P, Milla CE, Marshall B, LaVange L, Engels J, Mathews D, Schaberg A, Williams J, Ramsey B, for the Cystic Fibrosis Foundation Therapeutics Development Network. Safety and Tolerability of Denufosol Tetrasodium Inhalation Solution, a Novel P2Y2 Receptor Agonist: Results of a Phase 1/Phase 2 Multi-Center Study in Mild to Moderate Cystic Fibrosis. Pediatric Pulmonology 2005; 39:339348.

     Milla CE, Billings JL, Moran A. Diabetes is associated with dramatically decreased survival in women but not men with cystic fibrosis. Diabetes Care 2005; 28:2141-2144.

     Moss RB. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Medical Mycology 43:S203-S206, 2005.

     Groman JD, Karczeski B, Sheridan M, Robinson TE, Fallin MD, Cutting GR. Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis. J Pediatr. 2005 May;146(5):675-80.

2004 Publications

     Moss RB, Rodman D, Spencer LT, Aitkin ML, Zeitlin PL, Waltz D, Milla C, Brody A, Clancy JP, Ramsey B, Hamblett N, Heald A. Repeated AAV2 aerosol-mediated CFTR gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo controlled trial. Chest 125:509-521, 2004.

     Dorsaneo D, Borowitz D, Sharp J, Moss R. Allergic bronchopulmonary aspergillosis with normal serum IgE in a child with cystic fibrosis. Ped Asthma Allergy Immunol 17:146-150,2004.

     Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, Davies Z, Foy C, Noone PG, Knowles MR. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol. 2004 May;37(5):385-9

     Alper OM, Wong LJ, Young S, Pearl M, Graham S, Sherwin J, Nussbaum E, Nielson D, Platzker A, Davies Z, Lieberthal A, Chin T, Shay G, Hardy K, Kharrazi M. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. Hum Mutat. 2004 Oct;24(4):353.

     Moss RB. Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clin Ex Immunol 135:358-360, 2004.

     Milla CE. Association of nutritional status and pulmonary function in children with Cystic Fibrosis (Review). Curr Opin Pulm Med 2004; 10:505 - 509.

     Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K. Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. Pediatr Pulmonol. 2004 Nov 30; [Epub ahead of print]

     Bonnel AS, Song SM, Kesavarju K, Newaskar M, Paxton CJ, Bloch DA, Moss RB, Robinson TE. Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatr Pulmonol. 2004 Nov;38(5):396-405.

     Robinson TE. High-resolution CT scanning: potential outcome measure. Curr Opin Pulm Med. 2004 Nov;10(6):537-41.

     Croteau GA, Martin DB, Camp J, Yost M, Conrad C, Zeitlin PL, Heald AE. Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis. Ann Occup Hyg. 2004 Nov;48(8):673-81. Epub 2004 Oct 26.

     Alper OM, Wong LJ, Young S, Pearl M, Graham S, Sherwin J, Nussbaum E, Nielson D, Platzker A, Davies Z, Lieberthal A, Chin T, Shay G, Hardy K, Kharrazi M. Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients. Hum Mutat. 2004 Oct;24(4):353.

     Dorsaneo D, Borowitz D, Sharp J, Moss R. Allergic bronchopulmonary aspergillosis with normal serum IgE in a child with cystic fibrosis. Pediatric Asthma Allergy Immunology 2004; 17:146-50.

     Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, Davies Z, Foy C, Noone PG, Knowles MR. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatric Pulmonology. 2004 May;37(5):385-92

     Moss RB.Lymphocytes in cystic fibrosis lung disease: a tale of two immunities. Clinical and Experimental Immunology 2004 Mar;135(3):358-60.

     Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest. 2004 Feb;125(2):509-21

     Robinson TE, Raman R, Venkatraman R, Desai N, Shah S, Mishra N, Alper A, Sheikh F, Hajra S, Nadgir U, Nandini A, Moss RB. Effect of Pulmozyme therapy on quantitative airway measurements: results of a preliminary pilot study. American Journal of Respiratory and Critical Care Medicine 2004; 169:A391.

2003 Publications

     Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and Microbiologic Markers in Induced Sputum following IV Antibiotics in Cystic Fibrosis.American Journal of Respiratory and Critical Care Medicine 2003 Dec 15, 168(12):1471-5. Epub 2003 Sep 11.
Related Articles, Links
Medicine, Harvard Medical School, Children's Hospital, Boston, MA, USA.

     Moss R, Wagener J, Daines C, Hale K, Ahrens R, Gibson R, Anderson K, Retsch-Bogart G, Nasr S, Noth I, Waltz D, Zeitlin P, Ramsey B, Hamblett N, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b (IFN-g1b) effects on safety, bacterial counts, and pulmonary function in 66 patients with mild-moderate cystic fibrosis lung disease. Am J RespirCrit Care Med 167:A923, 2003.

     Brody AS, Campbell JD, Millard, Steven P, Moss RB, Heald AE. Relationship between FEV1 and high-resolution chest CT findings in CF patients with mild lung disease: baseline data from the AAV2 Phase II gene transfer study. Pediatr Pulmonol Suppl 25 319, 2003.

     Carter BJ, Munson K, Burstein H, Peluso R, Gerard C, Guggino W, Engelhardt J, Flotte T, Moss R. AAV-CFTR gene therapy for cystic fibrosis: retrospect and prospect. Pediatric Pulmonology Suppl 25: 159-160, 2003.

     Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan M, Wagener JG. Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann C, Aitken M, Mahl T Safety and preliminary clinical activity of a novel pancreatic enzyme preparation, Theraclec-Total for the treatment of exocrine pancreatic insufficiency. Pediatr Pulmonol Suppl 25; 339, 2003.

     Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Hamblett N, Borowitz D, Daines C, Hiatt P, Konstan M, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Zeitlin PL, Ramsey B. Duration of the anti-pseudomonal treatment effect of inhaled tobramcyin in young children with cystic fibrosis. Pediatr Pulmonol Suppl 25; 295, 2003.

     Robinson TE, Goris ML, Zhu JH, Valansani M, Kabanskaya Y, Moss RB. Regional effects of Pulmozyme therapy on air trapping during a 12 month intervention. Pediatr Suppl 25; 315-316, 2003.

     Robinson TE, Goris ML, Zhu JH, Chen X, Moss RB. Quantitative air trapping is associated with mucus plugging, extent and severity of bronchial wall thickness and bronchiectasis HRCT scoring. Pediatr Pulmonol Suppl 25; 316, 2003.

     Clancy JP, Eubanks V, Bebok Z, Franks K, Zeitlin P, Brass L, Aitken M, Gibson R, Gordon M, Lyons K, Berclaz L, Davies Z, Foy C, Callahan T, Sorscher E, Bedwell D. A randomized, double-blind trial of topical gentamicin and tobramycin to improve CFTR function in CF patients with and without premature stop mutations. Pediatr Pulmonol Suppl 25; 250-1 2003.

     Steinbach WJ, Stevens DA, Denning DW, Moss RB. Advances against aspergillosis. Clinical Infectious Diseses 2003 Oct 1;37 Suppl 3:S155-6.
Related Articles, Links
Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University, Durham, North Carolina, USA. stein022@mc.duke.edu

     Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.Human Gene Therapy2003 Jul 20;14(11):1079-88.
Related Articles, Links
Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610-0296, USA. flotttr@peds.ufl.edu

     Robinson TE, Leung AN, Northway WH, Blankenberg FG, Chan FP, Bloch DA, Holmes TH, Moss RB. Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease. American Journal of Respiratory and Critical Care Medicine 2003 Sep 1;168(5):588-93. Epub 2003 May 13.

Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Human Gene Therapy, 2003 Jul 20;14(11):1079-88.

     Stevens DS, Moss R, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody A, Light M, Skov M, Maish G, Mastella G, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Cystic Fibrosis Foundation Consensus Conference. Clinical Infectious Diseases; 2003 Suppl 3

     Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group.Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 167:841-9, 2003.

     Moss RB, Rodman D, Spencer LT, Aitkin ML, Zeitlin PL, Waltz D, Milla C, Brody A, Clancy JP, Ramsey B, Hamblett N, Heald A. Repeated AAV2 aerosol-mediated CFTR gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Submitted.

      Goris ML, Zhu HJ, Blankenberg F, Chan F, Robinson TE. An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Chest 123:1655, 2003

Publications prior to 2003:

     Moss, RB. Allergic bronchopulmonary aspergillosis Clin Rev Allergy Immunol, 2002 Aug; 23(1):87-104

     Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW,Desch JK, Norbash AM, Conrad CK, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Reynolds TC, Moss RB, Gardner P. A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies. Human Gene Therapy, 2002 Jul 20;13(11):1349-59

     Davies, Zoë. Cystic Fibrosis. Nurseweek, May 7, 2002.

     Moss RB. Long-term Benefits of Inhaled Tobramycin in Adolescent Patients With Cystic Fibrosis. Chest, 2002;121:55-63.

     Crosier, Janice. Coming of Age. Nursing Management, November, 2001.

     Mak GK, Henig NR. Sinus disease in cystic fibrosis.Clin Rev Allergy Immunol 2001 Aug; 21(1):51-63

     Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest, 120:107-113S, 2001.

     Robinson TE, Leung AN, Northway WH, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Moss RB. Spirometer-triggered high resolution CT and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. Journal of Pediatrics, 2001, Apr;138(4):553-9.

     Henig NR, MR Tonelli, MV Pier, JL Burns, ML Aitken. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001, Apr;56(4):306-11.

     Wine JJ, Kuo E, Hurlock G, Moss RB.Comprehensive mutation screening in a cystic fibrosis center. Pediatrics, 2001 Feb;107(2):280-286

     Moss, Richard B.New Approaches to Cystic Fibrosis Hospital Practice (Online) 2001, Jan15.

      Yee K, Robinson C, Hurlock G, Moss RB, Wine JJ. Novel cystic fibrosis mutation L1093P: functional analysis and possible Native American origin. Hum Mutat (Online) 15:208; 2000.

     Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000 Jun;120(3):518-25.

     Evans ME, Jordan CT, Chang SMW, Conrad C, Gerberding JL, Kaufman HL, Mayhall CG, Nolta, JA, Pilaro AM, Sullivan S, Weber DJ, and Wivel NA. Clinical infection control in gene therapy: A multidisciplinary conference. Infection Control and Hospital Epidemiology. 2000. 21:659-673.

    Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev M, et al for the Cystic Fibrosis Inhaled Tobramycin Study Group (incl Moss R).Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. The New England Journal of Medicine 340: 23-30, 1999.

     Nepumuceno I, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 115: 364-370, 1999.

     Wagner JA, Nepumuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, Moss RB, Wine JJ, Gardner P. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials.The Journal of Gene Medicine 1:13-21, 1999.

     Smith AL, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson D, Yogev R. Comparison of a Beta-lactam alone versus Beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. The Journal of Pediatrics 134:413-421, 1999.

     Robinson TE, Leung AN, Moss RB, Blankenberg FG, Northway, WH. Standardized high-resolution CT of the lung using a spirometer-gated electron beam CT scanner. The American Journal of Roentgenology 172:1636-1638; 1999.

     Wagner JA, Vassilakis A, Hurlock G, Moss RB, Wine JJ. Two novel CFTR mutations in a cystic fibrosis patient of Chinese origin. Human Genetics. 104:511-515; 1999.

     Illek B, Zhang L, Lewis NC, Moss RB, Dong J-Y, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is normalized by genistein.American Journal of Physiology. 277:C833-C839; 1999.

     Wagner JA, Moran ML, Messner AH, Diafuku R, Kouyama D, Desch JK, Manley S, Norbash AM, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 108: 218-226, 1999.

     Mickle JE, Macek M, Fulmer-Smentek SB, Egan MM, Schwiebert E, Guggino W, Moss R, Cutting GR. A mutation in the cystic fibrosis transmembrane conductance regulator associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Human Molecular Genetics 7:729-735; 1998.

     Bhudhikanok GS, Wang M-C, Marcus R, Harkins A, Moss RB, Bachrach LK. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. The Journal of Pediatrics 133; 18-27; 1998.

     Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. A phase I/II study of tgAAV-CFTR for the treatment of chronic sinusitis in patients with cystic fibrosis. Human Gene Therapy 9:889-909; 1998.

     Wagner JA, Moran ML, Messner AH, Diafuku R, Kouyama D, Desch JK, Manley S,Norbash AM, Kang S, Conrad CK, Friborg S, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. Efficient and persistent gene transfer of AAV-CFTR in the CF maxillary sinus. The Lancet 351:1702-1703; 1998.

     Narayanan M, Conrad C, Hardy KA. Congenital Lobar Emphysema: An atypical presentation. Resident & Staff Physician 1997. 43(7): 26-30

     Henig NR, ML Aitken. Update on clinical trials of cystic fibrosis. Current Opinion in Pulmonary Medicine. 3: 404-9, 1997.

     Conrad CK, Sandra Allen, Sandra A. Afione, Thomas C. Reynolds, Ximena Barrazza-Ortiz, Robert Adams, Frederic B. Askin, William B. Guggino, Barrie J. Carter, and Terence R. Flotte. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Therapy 1996. 3:658-668.

     Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A Phase I study of aerosolized administration of tgAAVCF to CF patients with mild lung disease. Pediatr Pulmnol Suppl 20:236, 2000.

     Stroud P, Paxton C, Moss RB. Widespread underdiagnosis and non-CF Center based care for California CF patients. Submitted. Pediatr Pulmnol Suppl 20:236, 2000.316.

     Robinson TE, Leung AN, Moss RB, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Hubli S, Northway WH. Utility of spirometer-triggered high resolution computed tomography scores in assessing changes in cystic fibrosis patients before and after treatment for a pulmonary exacerbation. Pediatr Research 45:355A, 1999.

     Moss R, Kylstra JW, Gibson R. Who benefits more? An analysis of FEV1 and weight in adolescent (age 13-គ) CF patients using inhaled tobramycin (Tobi®). Pediatr Pulmnol Suppl 19:243, 1999.

     Wagner JA, Messner AH, Moran ML, Guggino WB, Flotte TR, Wine JJ, Carter BJ, Batson EP, Moss RB, and Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies. Pediatr Pulmnol Suppl 19:223, 1999.

     Robinson TE, Leung AN, Moss RB, Blankenberg FG, Bloch DA, Oehlert JW, Al-Dabbagh H, Northway WH. Assessment of spirometer-gated high resolution computed tomography of the chest in cystic fibrosis patients before and after treatment for a pulmonary exacerbation. Pediatr Pulmonol Suppl 17:334-335, 1998.

     Wagner JA, Messner AH, Friborg S, Reynolds T, Guggino WB, Moss RB, Wine JJ, Carter BJ, Flotte TR, Gardner P. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF in the maxillary sinus of CF patients. Pediatr Pulmonol Suppl 17:260, 1998.

     Robinson TE, Leung AN, Moss RB, Blankenberg FG, Northway WH. A new technique for evaluating air-trapping in CF patients using spirometer-gated high resolution CT scans during inspiratory/expiratory imaging. Pediatr Pulmonol Suppl 17:335, 1998.

     Wagner JA, Moran ML, Messner AH, Nepomuceno IB, Norbash AM, Conrad CK, Moss RB, Wine JJ, Gardner P. Maxillary sinusitis as a surrogate model for acute infectious exacerbations of CF lung disease. Pediatr Pulmonol Suppl 17:351, 1998.